NovobiocinNovobiocin - High-quality laboratory reagent available from Gentaur. Catalog: 804-HY-B0425-01.804-HY-B0425-01804-HY-B0425-01Business & Industrial > Science & LaboratoryNovobiocin
Gentaur
EUR12027-02-20

Novobiocin

CAT:
804-HY-B0425-01
Size:
5 mg

For Laboratory Research Only. Not for Clinical or Personal Use.

  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
Novobiocin - image 1

Novobiocin

  • Description:

    Novobiocin (Albamycin) is a potent and orally active antibiotic. Novobiocin also is a DNA gyrase inhibitor and a heat shock protein 90 (Hsp90) antagonist. Novobiocin has the potential for the research of highly beta-lactam-resistant pneumococcal infections. Novobiocin shows anti-orthopoxvirus activity[1][2][3][4][6].
  • Product Name Alternative:

    Albamycin; Cathomycin
  • UNSPSC:

    12352005
  • Hazard Statement:

    H302, H312, H332
  • Target:

    Antibiotic; Apoptosis; Bacterial; DNA/RNA Synthesis; HSP; Orthopoxvirus
  • Type:

    Natural Products
  • Related Pathways:

    Anti-infection; Apoptosis; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease
  • Applications:

    COVID-19-anti-virus
  • Field of Research:

    Cancer; Infection
  • Assay Protocol:

    https://www.medchemexpress.com/novobiocin.html
  • Concentration:

    10mM
  • Purity:

    97.88
  • Solubility:

    DMSO : 100 mg/mL (ultrasonic)
  • Smiles:

    CC1=C(O2)C(C(O)=C(NC(C3=CC(C/C=C(C)/C)=C(O)C=C3)=O)C2=O)=CC=C1O[C@H]4[C@@H]([C@@H]([C@@H](OC)C(C)(C)O4)OC(N)=O)O
  • Molecular Formula:

    C31H36N2O11
  • Molecular Weight:

    612.62
  • Precautions:

    H302, H312, H332
  • References & Citations:

    [1]Marcu MG, et al. The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. J Biol Chem. 2000 Nov 24;275 (47) :37181-6.|[2]Ali-Osman F, et al. Topoisomerase II inhibition and altered kinetics of formation and repair of nitrosourea and cisplatin-induced DNA interstrand cross-links and cytotoxicity in human glioblastoma cells. Cancer Res. 1993 Dec 1;53 (23) :5663-8.|[3]Rodríguez-Cerrato V, et al. Comparative efficacy of novobiocin and amoxicillin in experimental sepsis caused by beta-lactam-susceptible and highly resistant pneumococci. Int J Antimicrob Agents. 2010 Jun;35 (6) :544-9.|[4]Eder JP, et al. A phase I clinical trial of novobiocin, a modulator of alkylating agent cytotoxicity. Cancer Res. 1991 Jan 15;51 (2) :510-3. |[5]Bhatia S, et al. Targeting HSP90 dimerization via the C terminus is effective in imatinib-resistant CML and lacks the heat shock response.Blood. 2018 Jul 19;132 (3) :307-320.|[6]Smee DF. Progress in the discovery of compounds inhibiting orthopoxviruses in animal models. Antivir Chem Chemother. 2008;19 (3) :115-24. |[7]Smee DF. Progress in the discovery of compounds inhibiting orthopoxviruses in animal models. Antivir Chem Chemother. 2008;19 (3) :115-24.
  • Shipping Conditions:

    Blue Ice
  • Storage Conditions:

    -20°C (Powder, sealed storage, away from moisture)
  • Scientific Category:

    Natural Products
  • Clinical Information:

    Launched
  • Isoform:

    HSP90; β-lactam
  • Citation 01:

    BioRxiv. 2025 Sep 15.|J Med Virol. 2025 Oct;97 (10) :e70655.|Mol Pharm. 2022 Nov 7;19 (11) :4320-4332.|Nat Methods. 2023 Sep;20 (9) :1388-1399.|Adv Sci (Weinh) . 2022 Dec;9 (34) :e2203088.|Blood. 2018 Jul 19;132 (3) :307-320.|Cancer Res Commun. 2024 Apr 9;4 (4) :1024-1040.|Cell Rep Med. 2024 May 29:101592.|Int J Mol Sci. 2019 Mar 5;20 (5) . pii: E1125. |J Med Virol. 2025 Oct;97 (10) :e70655.|Surgery. 2024 Jun 18:S0039-6060 (24) 00303-9.
  • CAS Number:

    [303-81-1]